In previous studies, both P021 and its parent non-adamantylated peptide were found to rescue cognitive impairment, synaptic deficit, neuroinflammation, and tau and Aβ pathologies in rat and mouse models of AD (Blanchard et al., 2010; Chohan et al., 2011; Bolognin et al., 2014; Kazim et al., 2014; Baazaoui and Iqbal, 2017a,b). This evidence concerns the gene MAPT and Alzheimer disease.